Antibodies as Therapeutics
Since the development of the hybridoma method for monoclonal antibody production in 1975, the possibility of bioengineering their immunological capabilities for precise therapeutic usage could now be afforded. This term itself reflects its main idea: the words ‘hybrid’ and ‘myeloma’… Continue Reading
